Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2018-07-26 Earnings Release
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 26, 2018, reporting the results of operations and financial condition for the quarter ended June 30, 2018. It references a press release (Exhibit 99.1) containing the financial results. The text explicitly states that the information is being furnished and is not considered "filed" for certain regulatory purposes. The document is short (3597 characters) and primarily serves as an announcement of the earnings release rather than containing detailed financial statements or analysis itself. According to the classification rules, initial announcements of quarterly financial results are classified as Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2018-07-26 English
3
Director's Dealing
2018-05-23 English
FORM 4 -
Director's Dealing
2018-05-23 English
FORM 4 -
Director's Dealing
2018-05-23 English
FORM 4 -
Director's Dealing
2018-05-23 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 18, 2018, reporting the appointment of Geoffrey Hulme as interim Principal Executive Officer of Innoviva, Inc. The key content is about the hiring and appointment of a senior officer, including details of his compensation and indemnification agreement. There is no financial data or report content, but rather an announcement of a management change. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 7,719 characters, which is sufficient to contain substantive information about the management change. Therefore, the appropriate classification is MANG with high confidence.
2018-05-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.